Eli Lilly Sues Providers Over Unauthorized Sales of Diabetes Drug Mounjaro Amid Shortage

Eli Lilly sues medical spas, clinics, and pharmacies for allegedly selling unauthorized versions of diabetes drug Mounjaro
Lawsuits filed in multiple states amid shortage of Mounjaro due to high demand, partly for off-label weight loss
Clinics accused of selling "compounded" tirzepatide, active ingredient patented solely by Eli Lilly
Safety concerns as compounded drugs not FDA-approved and ingredients unclear
Actions similar to Novo Nordisk lawsuits over compounded Ozempic and Wegovy
FDA warned of risks from unauthorized Ozempic and Wegovy amid supply shortages

cnbc.com

Relevant topic timeline:

8/2/2023

Makers of Ozempic and Mounjaro sued over 'stomach paralysis' claims

Main Topic: Lawsuit alleges that Novo Nordisk and Eli Lilly failed to adequately warn patients about the risk of severe stomach problems associated with their diabetes drugs Ozempic and Mounjaro. Key Points: 1. Lawsuit claims that the drugs can cause gastrointestinal injuries, including severe gastroparesis and persistent vomiting. 2. GLP-1 agonists like Ozempic and Mounjaro can slow down food movement through the stomach, leading to feelings of fullness, but can also cause gastrointestinal issues. 3. Over 400 people have come forward claiming gastrointestinal injuries from the drugs, and the lawsuit expects thousands of similar cases.

9/7/2023

Weight-Loss Drug Market Can Hit $100 Billion, J.P. Morgan Says. That Makes Eli Lilly Stock a Big Winner.

Eli Lilly could potentially generate $50 billion in annual sales from weight-loss drugs by 2030, positioning the pharmaceutical company as a major beneficiary in the obesity treatment market, according to J.P. Morgan.

9/16/2023

Eli Lilly Poised for Massive Growth with Diabetes, Obesity Drugs and Potential Alzheimer's Blockbuster

Eli Lilly, a biotech giant known for its work in diabetes and obesity care, has the potential to provide a CAGR of nearly 16% and turn an initial investment of $1,000 into $2,500 by 2030, driven by its strong growth in the therapeutic area and promising pipelines in other fields like Alzheimer's disease.

10/12/2023

Eli Lilly Soars on Diabetes Drug Success and Promising Obesity Treatment

Shares of pharmaceutical company Eli Lilly are on the rise, driven by the growth potential of its diabetes and obesity products, leading analysts to predict that it could become the first trillion-dollar bio-pharma company. The company's recent approval of Mounjaro for treating type 2 diabetes has resulted in strong revenue growth, and there is anticipation that it will also gain FDA approval for treating obesity. Wall Street analysts are optimistic about Eli Lilly stock, with a consensus rating of Strong Buy.

Topics

Posted 9/19/2023, 8:33:05 PM